MARKET WIREYahoo Finance • 9h ago
Caribou Biosciences stock plunges 40% on halt of CAR-T programsYahoo Finance report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
Why CRBU Stock dropped -4.90% Today — RQD Quant Desk Flash
$0.42 -4.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.42
Caribou Biosciences Inc. (CRBU) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $47.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CRBU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CRBU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.42 (-4.90% 1D, market cap $47.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBU ranks #753 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CRBU compare to TIL and LONA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and LONA (LeonaBio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CRBU?
▼
Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.42 (-1.07%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRBU)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY CRBU SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.50-8% Next Q
41
Q2 (-2Q)Grade E$0.46+6.5% Next Q
38
Q3 (-1Q)Grade E$0.49-14.3% Next Q
36
CurrentGrade E$0.42-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CRBU Turnaround Squeeze
While CRBU currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.05) and Max Pain ($0.44) forces dealer call-delta covering toward $3.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRBU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRBU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CRBU Stock dropped -4.90% Today — RQD Quant Desk Flash
Caribou Biosciences Inc. (CRBU) dropped -4.90% to $0.42, trading at 2% of its 52-week range ($0.41 – $3.54). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.41 – $3.54) with RSI-14 at 27.5 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.42 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CRBU Headlines & Catalysts
MARKET WIREInvesting.com • 12h ago
Why is Caribou Biosciences stock collapsing today?Investing.com report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting News Network • 15h ago
Caribou Biosciences to Evaluate Strategic AlternativesInvesting News Network report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
RISK WATCHBenzinga • 18h ago
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's WhyBenzinga report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBioWorld News • 21h ago
Caribou alarm herd, stock plunges on ‘alternatives’ planBioWorld News report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
Caribou Biosciences, Inc. Stock 12‑Month Price Target Raised to $11, Implies 869% UpsideTradingView report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
RISK WATCHStock Titan • 1d ago
Two cancer cell therapy programs are set to stop development as Caribou plans job cutsStock Titan report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T ProgramsYahoo Finance report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 5d ago
Caribou Biosciences (CRBU) Stock Fair Value Falls After Clinical Programs Are HaltedCaribou Biosciences is back in focus after fair value estimates shifted from about US$11.86 to US$5.75 per share, echoing recent price target resets across Wall Street coverage. Analysts are reacting to halted clinical p
RISK WATCHYahoo • 3h ago
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue EstimatesTravere (TVTX) delivered earnings and revenue surprises of -120.00% and +16.64%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRBU)
- ✓Walkthrough of CRBU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CRBU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.01%▼ DESCENDING CHANNEL
2026-11-02O $0.49H $0.49L $0.42C $0.42VOL 2.84M
RES: $1.27SUP: $0.11SMA50: $1.05SMA200: $1.62
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CRBU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +11.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CRBU today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CRBU. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRBU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRBU)
Health Care Rank #753 of 1016
⚔️ TIL vs CRBU Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CRBU vs. TIL, LONA, IMA, KLRS)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Caribou Biosciences Inc. (CRBU) ranks #753 by composite RQD confidence (33/100, grade E) and #757 by equity capitalization ($47.7M). Within this direct 5-issuer industry benchmark cohort, CRBU leads on earnings valuation at N/A trailing P/E, while CRBU leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with CRBU at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRBU
ACTIVE
Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -4.90% | $47.7M | Benchmark Subject |
| TIL Instil Bio Inc. | D- | 39/100 | — | — | -35.0% | -0.37% | $46.3M | /til-vs-crbu → |
| LONA LeonaBio Inc. | D- | 36/100 | — | — | -35.0% | +0.61% | $46.3M | /lona-vs-crbu → |
| IMA ImageneBio Inc. | E | 19/100 | — | — | -35.0% | +1.24% | $46.0M | /ima-vs-crbu → |
| KLRS Kalaris Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -4.69% | $50.7M | /klrs-vs-crbu → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001619856In its most recent audited fiscal period (FY2025, filed 2025-12-31), Caribou Biosciences Inc. (CRBU) reported GAAP revenue of $11.2M (+11.7% vs. FY2024 revenue of $10.0M , and -67.6% cumulative change since FY2023) , GAAP net income of -$148.1M, operating cash flow of -$111.0M, and free cash flow of -$112.4M (+21.5% YoY). On the balance sheet, CRBU closed FY2025 with $175.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $11.2M | -$148.1M | -$111.0M | -$112.4M | $175.4M | — |
| FY2024 (FY) | 2024-12-31 | $10.0M | -$149.1M | -$138.2M | -$143.1M | $313.3M | — |
| FY2023 (FY) | 2023-12-31 | $34.5M | -$102.1M | -$93.3M | -$93.3M | — | — |
3. CRBU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CRBU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Caribou Biosciences Inc. (NASDAQ: CRBU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.42 (-4.90% 1D, market cap $47.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBU ranks #753 in composite RQD confidence.
How does CRBU compare to TIL and LONA in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRBU carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and LONA (LeonaBio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, CRBU leads on earnings multiple (N/A) while CRBU leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CRBU?
Per CRBU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001619856), Caribou Biosciences Inc. generated $11.2M in revenue (+11.7% YoY), -$148.1M in net income, and -$112.4M in free cash flow against $175.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CRBU trading relative to its 50-day, 200-day, and 52-week technical levels?
CRBU last traded at $0.42 (-4.90% on volume of 2,306,256 shares), positioning the stock -60.00% below its 50-day simple moving average ($1.05) and -74.07% below its 200-day simple moving average ($1.62). Across its 52-week range of $0.41 to $3.54, CRBU sits at the 0.3% percentile with a 14-day RSI of 27.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.47).
CRBU Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CRBU stock moving today?
Why CRBU Stock dropped -4.90% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 33/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CRBU — Caribou Biosciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:47:07Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CRBU scores 33 out of 100, which corresponds to a letter grade of E and a verdict label of "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 8 / 20. The source cites ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating a return on invested capital or free cash flow that would support valuation on cash-generation grounds.
- Whale 13F Flow: 3 / 20. This pillar reflects institutional accumulation and options positioning. The low score signals weak institutional support in the source data; no holder detail is provided to explain the drivers.
- Insider Conviction: 5 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider signaling of conviction in the source data.
- Macro Regime Fit: 6 / 20. The source cites a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is tracked at market-level volatility, but the score reflects weak alignment with the prevailing regime per the rating.
- Forensic Balance Sheet: 11 / 20. The source cites an Altman Z-Score of 2.5, a Piotroski F-Score of 4/9, and a Debt/Equity ratio of 0.5. These sit in a middle-to-weak band and point to balance-sheet fragility rather than strength.
Taken together, the rating frames CRBU as a high-risk situation where the primary upside case depends on events rather than current fundamentals. The price of $0.45 and the 52-week range of $0.41 to $3.54 show a steep decline, and the recent news wire reports a headline of a stock "plunges 40%" on a halt of CAR-T programs. A prospective investor should treat the rating as a warning that the stock's current valuation sits on uncertain future outcomes, not on demonstrated cash generation.
Business
Caribou Biosciences Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $0.0B on a rounded basis, while the market data section lists $47.7M. The source data does not describe specific products, customers, or revenue model beyond reported revenue figures in the financials. Revenue is reported at $11.2M for FY 2025, but the source does not attribute that revenue to particular products or counterparties.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $11.2M | $-148.3M | $-148.1M | N/A | $-112.4M | $12.4M | N/A |
| FY 2024 | $10.0M | $-166.6M | $-149.1M | N/A | $-143.1M | $16.3M | N/A |
| FY 2023 | $34.5M | $-116.1M | $-102.1M | N/A | $-93.3M | N/A | N/A |
Per the SEC financials, the company reported operating losses across all three periods, and net losses of $-148.1M in FY 2025 and $-149.1M in FY 2024. Revenue declined from $34.5M in FY 2023 to $10.0M in FY 2024 before rising to $11.2M in FY 2025. The market data section cites operating margin and net margin of -60% and gross margin of 0%. The rating cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 4/9, and the market data cites ROIC of -35%. Cash is reported at $12.4M for FY 2025 against FCF of $-112.4M, and debt is not available in source data for any period.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the most prominent item is a headline reporting that the stock plunged 40% on the halt of CAR-T programs, flagged as a market wire item. A second item, flagged as a risk watch item, reports shares falling 35% after hours. Another headline reports the company will evaluate strategic alternatives, and a further item describes a "strategic alternatives" plan as a trigger for a herd-driven decline. One item carries a green catalyst flag, reporting a price target raised to $11 with implied upside of 869%. Per the butterfly supply-chain graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, there are no upstream or downstream dependencies, no sector correlations, and no proprietary signals recorded. The source data therefore does not identify specific supplier, customer, or sector linkages. An investor should note that the news flow references the halt of CAR-T programs, which is a pipeline-level event; the source does not map which partners, suppliers, or downstream programs are affected. Watch for any future disclosure that clarifies collaborative or manufacturing dependencies, since the current source is silent on these.
Open Questions
- What specific CAR-T programs were halted, and what is the disclosed financial impact on the company's pipeline and revenue base?
- What is the nature and timing of the strategic alternatives review, and what outcomes are under consideration?
- What is the company's debt position, since debt is listed as N/A across all reported periods?
- What is the cash runway implied by FY 2025 cash of $12.4M against FCF of $-112.4M?
- What drove the FY 2025 revenue recovery to $11.2M, and how durable is that revenue source?
CRBU Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Caribou Biosciences Inc. (CRBU) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 9h ago
Caribou Biosciences stock plunges 40% on halt of CAR-T programs Yahoo Finance report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 12h ago
Why is Caribou Biosciences stock collapsing today? Investing.com report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing News Network • 15h ago
Caribou Biosciences to Evaluate Strategic Alternatives Investing News Network report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Benzinga • 18h ago
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why Benzinga report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE BioWorld News • 21h ago
Caribou alarm herd, stock plunges on ‘alternatives’ plan BioWorld News report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
Caribou Biosciences, Inc. Stock 12‑Month Price Target Raised to $11, Implies 869% Upside TradingView report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Stock Titan • 1d ago
Two cancer cell therapy programs are set to stop development as Caribou plans job cuts Stock Titan report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
CRBU Stock Crashes 35% Premarket — RBC Slashes Target By 90% After Caribou Scraps CAR-T Programs Yahoo Finance report covering Caribou Biosciences Inc. (CRBU) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CRBU Bull vs. Bear Conversation Board — What's Your Call at $0.42?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRBU 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.40 (-11.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CRBU (E • RQD 33/100) a Buy at $0.45?
Welcome to the CRBU (Caribou Biosciences Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.35 (-22.2%)
Spot @ $0.45 Pump the brakes on CRBU — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CRBU, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Caribou Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.54 (+20.0%)
Spot @ $0.45 CRBU cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CRBU, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.45 (52-wk range $0.41 - $3.54), any beat on forward guidance forces shorts and underweight funds to chase.